Our team
A highly qualified gender-balanced team with a strong background both in female fertility area and in the OXO-001 drug development project.
Agnès Arbat I CEO I CMO
Agnès received her M.D. from the Autonomous University of Barcelona and is a Clinical Pharmacologist Specialist. She has 14 years of experience in the pharmaceutical industry. The last 10, leading the ‘Women’s Health and Cardiovascular Therapeutic Area Medical team. She has 11 indexed international papers, over 40 communications in international congresses, over 20 clinical trials led in the W.H. area, and over ten products or new indications launched. She is also a Mentoring Master of ‘Industria Farmacèutica i Biotecnologia’ ‘UPF’s students. She has been responsible for the clinical development and the management of Oxolife since its foundation (2013).
Ignasi Canals I CSO
Ignasi holds a Ph.D. in Molecular biology from the University of Barcelona. His doctoral thesis was focused on the OXO-001 mechanism of action. He started his professional career in biomedical research institutes. He spent 11 years in the pharmaceutical industry as a scientific advisor in Women’s Health, leading clinical studies, and research projects. He has 12 indexed international papers and 37 communications in national and international congresses. He has also participated in 2 public research programs funded by Spain/E.U. He has been responsible for R&D in Oxolife since its foundation (2013).
Rosa Torres I Science Project Manager and CMC lead
Rosa holds a Ph.D. in Pharmacy, and her doctoral thesis was focused on PCOS drug development. She is experienced in Women’s health R&D and project management in the pharmaceutical industry. From her background in Pharma, she provides Oxolife with knowledge in CMC, together with Intellectual Property management.
Marta Llorens I Clinical Trials Operations, Regulation, and Compliance Manager
Marta is oncology nurse with more than 20 years’ experience in drug investigation in the pharmaceutical industry and Clinical Research Organizations. She has overseen and coordinated oncology clinical trials as a project manager, Clinical Operations Manager, up to project’s Senior Director, and site manager. In Oxolife, she leads the Phase I and phase II implantation clinical trial from the operational and regulatory perspective, applying all her expertise in quality assurance.
José Bellver I International Investigator Coordinator
José holds a Ph.D. in Medicine and Surgery and is specialist in Gynaecology, Reproduction, and Obstetrics at Hospital La Fe in Valencia (Spain). Full professor at the University of Valencia. He has more than 90 indexed papers and 108 books. He is a reviewer in 22 journals on Human reproduction and Gynaecology and he has also participated in 9 public research programs funded by Spain/EU.
Agustí Soler I CFO
Agustí holds a Master in Corporate & Finance and Accounting & Auditing Expertise. He is specialised in finances, accounting, and audit of Venture Capital & Start-ups, with broad expertise in financial due diligence and corporate valuations, accounting, and consolidation under IFRS. He has outstanding experience in finances and operations direction with more than 12 years of experience in a Top 5 firm.
Juan García-Velasco I International Investigator Coordinator
Juan García-Velasco, MD, PhD, is Director of IVI Madrid. He is Professor of Obs&Gyn at the Rey Juan Carlos University of Madrid (Spain), and Director of their Master’s in Human Reproduction. He is the Principal Investigator of public funded projects, and has received awards from the SEF, SEGO and ESHRE. He has published more than 200 indexed articles and 30 chapters on Human Reproduction and Endometriosis, and is the Co-Editor of the Reproductive BioMedicine (RBM) Online journal.
Abel Riera I BD Advisor
Abel Riera has broad expertise in BD&L, M&A, business planning, market research and forecasting gained throughout his career in pharma and biotech. While heading Global Business Development and Portfolio at women health care focused Exeltis, he was instrumental to several transactions, including licensing in and out, divestitures and distribution deals. He has held positions of high relevance and breadth at Amgen, Almirall, SymBio Pharmaceuticals, Allergan and Galderma. He holds a degree in Economics from the University of Barcelona and an MBA from Pittsburg State University.
